These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 2511908)

  • 21. [The efficacy of combined use of 1 alpha-hydroxyvitamin D3 with calcium supplements in the treatment of osteoporosis].
    Yoshikawa S; Ohno A; Moro K; Matsumoto M; Nemoto H; Seki H; Kaneko N; Hosokawa O; Ishijima H
    Nihon Seikeigeka Gakkai Zasshi; 1988 Aug; 62(8):723-32. PubMed ID: 3235892
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Renal osteodystrophy. Effect of hemodialysis and 1 alpha-hydroxy vitamin D3 on bone lesions and metacarpal bone mass.
    Andresen J; Nielsen HE; Johannsen A
    Acta Radiol Diagn (Stockh); 1980; 21(4):541-4. PubMed ID: 7457184
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 1alpha-hydroxyvitamin D2 is less toxic but not bone selective relative to 1alpha-hydroxyvitamin D3 in ovariectomized rats.
    Weber K; Goldberg M; Stangassinger M; Erben RG
    J Bone Miner Res; 2001 Apr; 16(4):639-51. PubMed ID: 11315991
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Bone metabolic disorders due to antiepileptic drugs and the therapeutic effect of vitamin D2].
    Song FS; Zhou SS; Yang DZ
    Zhonghua Nei Ke Za Zhi; 1991 Jan; 30(1):33-4, 61. PubMed ID: 2032494
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 1 alpha-hydroxy vitamin D3 treatment of non-dialyzed patients with chronic renal failure. Effects on bone, mineral metabolism and kidney function.
    Nielsen HE; Rømer FK; Melsen F; Christensen MS; Hansen HE
    Clin Nephrol; 1980 Mar; 13(3):103-8. PubMed ID: 7379358
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effect of oxcarbazepine on bone metabolism.
    Cetinkaya Y; Kurtulmuş YS; Tutkavul K; Tireli H
    Acta Neurol Scand; 2009 Sep; 120(3):170-5. PubMed ID: 19719808
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of renal bone disease with 1 alpha-hydroxylated derivatives of vitamin D3. Clinical, biochemical, radiographic and histological responses.
    Kanis JA; Cundy T; Earnshaw M; Henderson RG; Heynen G; Naik R; Russell RG; Smith R; Woods CG
    Q J Med; 1979 Apr; 48(190):289-322. PubMed ID: 504552
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effect of valproate on bone mineral density in adult epileptic patients.
    Boluk A; Guzelipek M; Savli H; Temel I; Ozişik HI; Kaygusuz A
    Pharmacol Res; 2004 Jul; 50(1):93-7. PubMed ID: 15082034
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Pregnancy induced hypertension (PIH) and osteoporosis].
    Morikawa H; Chough SY; Ohara N; Yamasaki M; Ueda Y; Deguchi M; Mochizuki M
    Nihon Naibunpi Gakkai Zasshi; 1989 Oct; 65(10):1123-34. PubMed ID: 2591603
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of bone mineral density in children receiving carbamazepine or valproate monotherapy.
    Chou IJ; Lin KL; Wang HS; Wang CJ
    Acta Paediatr Taiwan; 2007; 48(6):317-22. PubMed ID: 18437965
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Quantitative assessment of bone density on X-ray picture.
    Inoue T; Kusida K; Miyamoto S; Sumi Y; Orimo H; Yamashita G
    Nihon Seikeigeka Gakkai Zasshi; 1983 Dec; 57(12):1923-36. PubMed ID: 6676402
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of osteopenia in children with insulin-dependent diabetes mellitus: the effect of 1 alpha-hydroxyvitamin D3.
    Al-Qadreh A; Voskaki I; Kassiou C; Athanasopoulou H; Sarafidou E; Bartsocas CS
    Eur J Pediatr; 1996 Jan; 155(1):15-7. PubMed ID: 8750803
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Alphacalcidol in the treatment of osteopenic syndrome in patients with bronchial asthma].
    Kochetkova EA; Gel'tser BI
    Ter Arkh; 2002; 74(3):32-5. PubMed ID: 11980117
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A 12-month longitudinal study of calcium metabolism and bone turnover during valproate monotherapy.
    Verrotti A; Agostinelli S; Coppola G; Parisi P; Chiarelli F
    Eur J Neurol; 2010 Feb; 17(2):232-7. PubMed ID: 19682062
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Osteoporotic changes in rheumatoid arthritis--longitudinal bone mass study and effect of 1 alpha-hydroxyvitamin D3].
    Teshima R
    Nihon Seikeigeka Gakkai Zasshi; 1988 Mar; 62(3):171-8. PubMed ID: 3392446
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adverse effects of antiepileptic drugs on bone mineral density.
    Babayigit A; Dirik E; Bober E; Cakmakci H
    Pediatr Neurol; 2006 Sep; 35(3):177-81. PubMed ID: 16939856
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Effect of 1-alpha oxyvitamin D3 on bone tissue in systemic osteoporosis].
    Rodionova SS; Zatsepin ST; Shvets VN
    Ortop Travmatol Protez; 1989 Feb; (2):37-40. PubMed ID: 2726218
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Daily oral 25-hydroxycholecalciferol supplementation for vitamin D deficiency in haemodialysis patients: effects on mineral metabolism and bone markers.
    Jean G; Terrat JC; Vanel T; Hurot JM; Lorriaux C; Mayor B; Chazot C
    Nephrol Dial Transplant; 2008 Nov; 23(11):3670-6. PubMed ID: 18579534
    [TBL] [Abstract][Full Text] [Related]  

  • 40. X-ray photodensitometric analysis of anticonvulsant-induced osteopathy.
    Iwata Y; Amano K; Kawamura H; Tanikawa T; Kawabatake H; Notani M; Iseki H; Shiwaku T; Nagao T; Taira T
    Jpn J Psychiatry Neurol; 1988 Sep; 42(3):594-6. PubMed ID: 3241486
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.